Fourth Capital Injection After Wholly-Owned Conversion: HSBC Life Plans to Increase Capital by 556 Million

```

The confidence that foreign-funded insurance companies have in the Chinese market is being demonstrated through tangible capital investments.

On January 8, HSBC Life released an announcement, revealing that its sole shareholder, HSBC Insurance (Asia), plans to inject 556 million yuan in additional capital into the company. Upon completion, HSBC Life’s registered capital will increase from 2.676 billion yuan to 3.232 billion yuan.

This capital increase was already approved by shareholder written resolution on January 6, 2026 but still needs regulatory approval to take effect.

This is HSBC Life’s fourth capital increase since becoming a wholly foreign-owned life insurance company.

HSBC Life was established in 2009 as a joint venture. In June 2022, it officially became a wholly owned foreign subsidiary of HSBC Insurance (Asia).

Concurrently with the completion of the equity change, the shareholder invested an additional 635 million yuan, followed by further capital injections of 654 million yuan in 2023 and 362 million yuan in 2025.

These three capital increases pushed its registered capital from the initial 1.025 billion yuan up to 2.676 billion yuan.

Behind these capital increases are dual drivers of capital needs from business expansion and strategic planning.

In 2024, HSBC Life’s performance saw significant improvement, with insurance business income reaching 13.089 billion yuan, a 79% increase year-on-year, successfully turning losses into profits with a net profit of 195 million yuan.

The rapid expansion of business scale increased capital consumption, and this capital injection will directly improve its solvency and provide a safety cushion for future development.

HSBC Life’s development strategy highlights the core advantage of “synergy between banking and insurance.”

Relying on HSBC Bank’s channel resources, the company focuses on high-net-worth clientele, embedding insurance products into the wealth management ecosystem to form a dual “wealth + health” growth engine model;

Regional expansion is also accelerating, with new branch offices opening in Sichuan, Jiangsu, and other areas in 2024, further improving its national network.

As an important part of HSBC Group’s presence in the Asian market, HSBC Life’s continued capital increases are a direct vote of confidence from foreign investors in the long-term growth potential of China’s insurance market.

Currently, the industry faces multiple challenges such as low interest rates and asset shortages, but foreign investors’ increased commitment against the trend conveys strong confidence in the domestic market. If approved by regulators, this capital injection will bring additional momentum for HSBC Life’s business expansion in 2026.

Risk Warning and DisclaimerThe market has risks; investments should be made cautiously. This article does not constitute individual investment advice and has not taken into account the special investment goals, financial situation, or needs of any particular user. Users should consider whether any opinions, views, or conclusions in this article apply to their specific circumstances. Invest accordingly at your own risk. ```